{"disease":{"id":"advanced-neuroendocrine-carcinoma","name":"advanced neuroendocrine carcinoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02628067","title":"Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1609,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT02611024","title":"Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":316,"lead_sponsor_name":"PharmaMar","has_results":false},{"nct_id":"NCT01010126","title":"Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":252,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05969860","title":"At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06577987","title":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"Circle Pharma","has_results":false},{"nct_id":"NCT05015621","title":"A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":194,"lead_sponsor_name":"Hutchison Medipharma Limited","has_results":false},{"nct_id":"NCT05058651","title":"Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":189,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06157827","title":"A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":178,"lead_sponsor_name":"Nanjing Leads Biolabs Co.,Ltd","has_results":false},{"nct_id":"NCT06424665","title":"A Study of FZ-AD005 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":162,"lead_sponsor_name":"Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT07080242","title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"SystImmune Inc.","has_results":false},{"nct_id":"NCT02893917","title":"Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":90,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT05126433","title":"Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"Jazz Pharmaceuticals","has_results":true},{"nct_id":"NCT06176989","title":"Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06062745","title":"Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT07520357","title":"A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":23,"lead_sponsor_name":"Beijing GoBroad Hospital","has_results":false},{"nct_id":"NCT03736720","title":"Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":11,"lead_sponsor_name":"Roswell Park Cancer Institute","has_results":true}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}